Startups
City Therapeutics
Develops RNA interference medicines using engineered small interfering RNAs to silence disease-related genes. Its pipeline includes programs targeting Factor XI for thromboembolic disease, RBP4 for Stargardt disease and TFR2 for anemia of chronic disease, alongside technology intended to extend RNAi medicines to additional tissues and therapeutic areas.
Team
Andy OrthChief Executive Officer and Board Director |
Anna O’DriscollChief Human Resources Officer |
 Ari NowacekSVP, Corporate Development |
Baisong MeiChief Medical Officer |
 Barry GreeneBoard Director |
Hans-Peter VornlocherScientific Advisor |
Ian MacRaeScientific Advisor |
 John MaraganoreCo-Founder and Executive Chair |
Keith RegnanteChief Financial Officer |
Kotaro NakanishiCo-Founder |
Maha RadhakrishnanBoard Observer |
Mark KeatingCo-Founder |
Mary Beth DeLenaChief Legal Officer and Secretary |
Phillip ZamoreCo-Founder |
 Robert NelsenBoard Director |
Rohan NirodyBoard Observer |
Ron PhilipBoard Director |
Sara NochurBoard Director |
Sebastian TrousilChief Operating Officer |
Tracy ZimmermannChief Scientific Officer |
Yukihide TomariCo-Founder |